theheart.org: Hypertension studies and news. Partnership with ASH

heartbriefs

Sen Grassley questions top medical schools about ghostwriting

Nov 20, 2009 13:15 EST

As part of his mission to see more financial transparency in medicine, Sen Grassley has asked eight top US medical schools about their policies on ghostwriting.

Medscape Medical News

ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment

Nov 19, 2009 14:00 EST

New 10-year mortality and morbidity data confirm the original trial conclusions, they say, that while amlodipine and lisinopril are not superior to chlorthalidone on any outcome, chlorthalidone is superior to these agents on one or more secondary end points. Full agreement with this conclusion in the community, though, is still hard to come by.

News

EFFECT: Public reporting of hospital performance improves quality of care?

Nov 19, 2009 10:00 EST

Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes.

Heart failure

HEAAL: High-dose trumps low-dose ARB for heart failure in the ACE-inhibitor intolerant

1 COMMENT - Nov 17, 2009 08:15 EST

UPDATED WITH COMMENTARY // The randomized trial, which compared losartan dosages of 150 mg/day and 50 mg/day, "makes a strong case for the value of incremental inhibition of the renin-angiotensin system," its authors say.

Prevention

Canadian confusion: Primary-care docs lack knowledge of CVD risk factors, prevention

8 COMMENTS - Nov 15, 2009 09:00 EST

Family doctors and general practitioners in Canada are confused about cardiovascular risk assessment in primary prevention, a new survey reveals.

News

What's going to be hot at AHA 2009?

2 COMMENTS - Nov 11, 2009 09:00 EST

Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.

Medscape Medical News

Echocardiographic evidence of PAH often doesn't trigger referral to a specialist

Nov 10, 2009 11:00 EST

Only one in four patients with echocardiographic evidence of pulmonary arterial hypertension is being referred for further evaluation.

Hypertension

Ambrisentan effective long-term for pulmonary arterial hypertension

1 COMMENT - Nov 9, 2009 17:00 EST

New data from the extension phase of two pivotal trials of the endothelin-receptor antagonist ambrisentan support its use as part of a long-term strategy for the treatment of pulmonary arterial hypertension.

Arrhythmia/EP

Obesity may top hypertension as risk factor for LA enlargement

Nov 9, 2009 17:00 EST

Obesity and hypertension were major independent risk factors for left atrial enlargement (itself a risk factor for atrial fibrillation) in an observational, population-based study, but obesity was the strongest predictor.

Lipid/Metabolic

Not all metabolic syndrome is created equal: Framingham Offspring analysis

3 COMMENTS - Nov 5, 2009 11:45 EST

The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.

Hypertension

Adding fuel to the J-curve fire; debate is reignited

2 COMMENTS - Nov 4, 2009 14:30 EST

More discussion about the J-curve in hypertension is published this week; one expert believes the undue attention being paid to this subject might discourage doctors from treating high blood pressure aggressively.

Prevention

Another in-hospital CV risk marker: 24-hour shifts with overnight on-call duty

1 COMMENT - Nov 4, 2009 09:45 EST

Long work shifts with nighttime on-call duty, with the inevitable interruptions of sleep, are associated with ECG, blood-pressure, and biochemical changes associated with increased cardiovascular risk, suggests a randomized crossover study that hints at a sustained effect on the risk markers if the 24-hour shifts happen too frequently.

Interventional/Surgery

US updates advice on perioperative beta-blocker use in noncardiac surgery

6 COMMENTS - Nov 3, 2009 14:30 EST

A US update on the perioperative use of beta blockers for noncardiac surgery is, says the lead author, "similar" to recent European guidance on this issue.

Hypertension

Combined home/GP hypertension control program successful in Pakistan

3 COMMENTS - Nov 2, 2009 17:00 EST

A synergistic approach of educating general practitioners about hypertension control together with a program to send lay workers into people's homes to educate them about the management of high blood pressure has proven successful in low- to middle-income households in Pakistan.

Clinical cardiology

ACE inhibitors of benefit in ischemic heart disease patients with preserved LV function

8 COMMENTS - Oct 19, 2009 17:00 EDT

Patients with ischemic heart disease and preserved LV function on standard therapy will gain additional benefit from taking ACE inhibitors, a new review concludes. The same cannot be said for ARBs, a drug class for which the evidence is much weaker, but these are a good substitute in those who cannot tolerate ACE inhibitors, the authors say.

heartbriefs

Expanded indication for telmisartan

3 COMMENTS - Oct 19, 2009 13:30 EDT

The drug can now be used to reduce the risk of MI, stroke, or death from cardiovascular causes in patients 55 years of age or older who are intolerant to ACE inhibitors but at high risk for cardiovascular events.

Acute Coronary Syndromes

Racial background woefully underreported in CV trials

1 COMMENT - Oct 15, 2009 13:15 EDT

Two-thirds of the 156 trials considered by the AHA in preparing a recent guideline failed to even record the ethnic backgrounds of participants, a new study has found. The researchers call for the reporting of race/ethnicity to be mandatory in all clinical trials, and they suggest medical journals should enforce this policy.

Hypertension

Diuretics effective as second-line therapy for hypertension

21 COMMENTS - Oct 13, 2009 12:00 EDT

Diuretics, especially hydrochlorothiazide, are as effective when given as second-line therapy for high blood pressure as they are when used as initial treatment, according to the first review to look at this issue.

Hypertension

High adherence to antihypertensive therapy lowers cardiovascular risk

Oct 9, 2009 13:30 EDT

Newly diagnosed hypertensive individuals who stuck to their antihypertensive therapy had a significantly lower risk of cardiovascular events than low adherers.

heartbriefs

Mercury/blood-pressure link should guide fish choices

1 COMMENT - Oct 6, 2009 16:45 EDT

An association seen between mercury levels and blood pressure, even after considering omega-3s and selenium, has researchers warning about the need to weigh the risks and benefits of fish consumption and to steer clear of bigger predators.

Hypertension

China death toll due to hypertension worse than predicted

1 COMMENT - Oct 6, 2009 14:15 EDT

The first prospective study using real data to inform the number of people suffering from and dying due to high blood pressure in China finds the problem is much worse than previously thought. A number of initiatives are planned to try to tackle this crisis.

Prevention

Simple, fixed-dose drug bundle may lower MI and stroke risk

4 COMMENTS - Oct 6, 2009 10:15 EDT

A bundle of medium doses of a statin and an ACE inhibitor appears to lower CV risk in high-risk individuals, an observational study suggests, but critics caution that these are early days.

Clinical cardiology

New "principles" on authorship and COI from PhRMA get mixed response

3 COMMENTS - Oct 2, 2009 12:00 EDT

The "Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results" echo recent standards set by medical journal editors, but some observers say the document, which has no penalty component, lacks real teeth.

Prevention

Time to act: Cardiologists, diabetes docs, and psychiatrists urged to work together to tackle CVD in the mentally ill

Sep 30, 2009 14:00 EDT

Doctors from across the specialties of cardiology, diabetes, and psychiatry are being urged to collaborate to improve care for the mentally ill, who are more likely to die from cardiovascular disease than any other cause.

Interventional/Surgery

BCIS-1 trial: "Bailout" intra-aortic balloon pump beats elective use in low EF/high-risk patients

1 COMMENT - Sep 29, 2009 10:45 EDT

The study provides an important answer to a question that has divided some interventionalists. Those who "swear" by IABP use for all high-risk, low-EF patients should rethink their practice. In hypotensive patients and those with cardiogenic shock, IABPs play a key role.

	No
	Yes